Regeneron Pharmaceuticals (NASDAQ:REGN) said the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...

Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...

Breast cancer and basal cell carcinoma were the most prevalent malignancies in patients with MS undergoing long-term DMT treatment.

Regeneron on Friday said the recommendation covers adults with adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor, ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous ...

Researchers sought to determine whether CAR-T therapy with ide-cel would be effective in patients with triple-class–exposed relapsed/refractory MM.

More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.

Planning Activities Are Ongoing for Next Phase of Cemsidomide Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma; Trials ...

Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 15.06%, which has investors questioning if this is right time ...